2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of …
CT January, LS Wann, H Calkins, LY Chen… - Circulation, 2019 - Am Heart Assoc
The purpose of this document is to update the “2014 AHA/ACC/HRS Guideline for the
Management of Patients With Atrial Fibrillation” S1. 3-1 (2014 AF Guideline) in areas for …
Management of Patients With Atrial Fibrillation” S1. 3-1 (2014 AF Guideline) in areas for …
2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint …
Writing Committee Members, CM Otto… - Journal of the American …, 2021 - jacc.org
The recommendations listed in this document are, whenever possible, evidence based. An
extensive review was conducted on literature published through March 1, 2020. Searches …
extensive review was conducted on literature published through March 1, 2020. Searches …
2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American …
CM Otto, RA Nishimura, RO Bonow… - Journal of the American …, 2021 - jacc.org
Aim This executive summary of the valvular heart disease guideline provides
recommendations for clinicians to diagnose and manage valvular heart disease as well as …
recommendations for clinicians to diagnose and manage valvular heart disease as well as …
[HTML][HTML] Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy …
1 ESGE recommends in patients with acute upper gastrointestinal hemorrhage (UGIH) the
use of the Glasgow–Blatchford Score (GBS) for pre-endoscopy risk stratification. Patients …
use of the Glasgow–Blatchford Score (GBS) for pre-endoscopy risk stratification. Patients …
Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group
Description: This update of the 2010 International Consensus Recommendations on the
Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding (UGIB) refines …
Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding (UGIB) refines …
Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage
SJ Connolly, M Sharma, AT Cohen… - … England Journal of …, 2024 - Mass Medical Soc
Background Patients with acute intracerebral hemorrhage who are receiving factor Xa
inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that …
inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that …
Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report
Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
J Steffel, P Verhamme, TS Potpara… - European heart …, 2018 - academic.oup.com
The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
[HTML][HTML] Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors
Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …